JP2005505586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505586A5 JP2005505586A5 JP2003532487A JP2003532487A JP2005505586A5 JP 2005505586 A5 JP2005505586 A5 JP 2005505586A5 JP 2003532487 A JP2003532487 A JP 2003532487A JP 2003532487 A JP2003532487 A JP 2003532487A JP 2005505586 A5 JP2005505586 A5 JP 2005505586A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- chromen
- amino
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- -1 cycloheteroalkyl Chemical group 0.000 claims 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- ILLXJTSTTAHMPW-ZZWBGTBQSA-N 2-bromo-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=CC=C1Br ILLXJTSTTAHMPW-ZZWBGTBQSA-N 0.000 claims 1
- BIGOYIJVKGTZJZ-HWYAHNCWSA-N 3,4-dimethoxy-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N(C)C1=CC=C(CCC(CN[C@H](C)C=2C=CC=CC=2)O2)C2=C1 BIGOYIJVKGTZJZ-HWYAHNCWSA-N 0.000 claims 1
- KTOFKMSCCFJWBS-VGOFRKELSA-N 4-amino-n-[(2r)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=C(N)C=C1 KTOFKMSCCFJWBS-VGOFRKELSA-N 0.000 claims 1
- KTOFKMSCCFJWBS-VGSWGCGISA-N 4-amino-n-[(2s)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=C(N)C=C1 KTOFKMSCCFJWBS-VGSWGCGISA-N 0.000 claims 1
- KTOFKMSCCFJWBS-PLEWWHCXSA-N 4-amino-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(N)C=C1 KTOFKMSCCFJWBS-PLEWWHCXSA-N 0.000 claims 1
- DQNREVMJMGBQKN-FKSKYRLFSA-N 4-amino-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(N)C=C1 DQNREVMJMGBQKN-FKSKYRLFSA-N 0.000 claims 1
- AWIXQIBWRFBSEK-PLEWWHCXSA-N 4-chloro-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(Cl)C=C1 AWIXQIBWRFBSEK-PLEWWHCXSA-N 0.000 claims 1
- FJNWVEWEYQRAJK-FKSKYRLFSA-N 4-chloro-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(Cl)C=C1 FJNWVEWEYQRAJK-FKSKYRLFSA-N 0.000 claims 1
- RRFQIUAANMAPNG-FKSKYRLFSA-N 4-fluoro-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(F)C=C1 RRFQIUAANMAPNG-FKSKYRLFSA-N 0.000 claims 1
- ZIOGBNJAFVMADK-FKSKYRLFSA-N 4-methoxy-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(CCC(CN[C@H](C)C=2C=CC=CC=2)O2)C2=C1 ZIOGBNJAFVMADK-FKSKYRLFSA-N 0.000 claims 1
- WZGAORUXLKNXSB-HWYAHNCWSA-N 4-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C)C=C1 WZGAORUXLKNXSB-HWYAHNCWSA-N 0.000 claims 1
- 108091005435 5-HT6 receptors Proteins 0.000 claims 1
- NCELXXSBJZTWHQ-NYRJJRHWSA-N 5-bromo-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(Br)S1 NCELXXSBJZTWHQ-NYRJJRHWSA-N 0.000 claims 1
- FWOQQSYVHAAAIO-FKSKYRLFSA-N 5-chloro-3-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-1-benzothiophene-2-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C4=C(C5=CC(Cl)=CC=C5S4)C)=CC=C3CC2)C)=CC=CC=C1 FWOQQSYVHAAAIO-FKSKYRLFSA-N 0.000 claims 1
- ITCPCWOZLJVHMY-NYRJJRHWSA-N 5-chloro-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(Cl)S1 ITCPCWOZLJVHMY-NYRJJRHWSA-N 0.000 claims 1
- YBSRWLPYDCLVSK-QRIPLOBPSA-N 5-chloro-n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2N(C)S(=O)(=O)C1=CC=C(Cl)S1 YBSRWLPYDCLVSK-QRIPLOBPSA-N 0.000 claims 1
- YQSSZSAYMFYLAK-NYRJJRHWSA-N 6-chloro-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C=4N5C=CSC5=NC=4Cl)=CC=C3CC2)C)=CC=CC=C1 YQSSZSAYMFYLAK-NYRJJRHWSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 150000007514 bases Chemical class 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- MPUPRKCXYAKXGG-CJFMBICVSA-N n-[(2r)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NC[C@@H]2OC3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 MPUPRKCXYAKXGG-CJFMBICVSA-N 0.000 claims 1
- ROQBLRJFXQWFLB-GCJKJVERSA-N n-[(2s)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C([C@H](OC1=C2)CN[C@H](C)C=3C=CC=CC=3)CC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-GCJKJVERSA-N 0.000 claims 1
- MPUPRKCXYAKXGG-NLFFAJNJSA-N n-[(2s)-2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NC[C@H]2OC3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 MPUPRKCXYAKXGG-NLFFAJNJSA-N 0.000 claims 1
- JUSHGQIHSMKQER-UHFFFAOYSA-N n-[2-(morpholin-4-ylmethyl)-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CN1CCOCC1 JUSHGQIHSMKQER-UHFFFAOYSA-N 0.000 claims 1
- KNXWOCYAYPNERT-UHFFFAOYSA-N n-[2-(thiomorpholin-4-ylmethyl)-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CN1CCSCC1 KNXWOCYAYPNERT-UHFFFAOYSA-N 0.000 claims 1
- KQVPFHLRRUPWLC-UHFFFAOYSA-N n-[2-[(1,2-diphenylethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNC(C=1C=CC=CC=1)CC1=CC=CC=C1 KQVPFHLRRUPWLC-UHFFFAOYSA-N 0.000 claims 1
- QDRJYKADDYSPBW-UHFFFAOYSA-N n-[2-[(1,3-benzodioxol-5-ylmethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=C2CCC(CNCC=3C=C4OCOC4=CC=3)OC2=CC=1NS(=O)(=O)C1=CC=CC=C1 QDRJYKADDYSPBW-UHFFFAOYSA-N 0.000 claims 1
- ORLIARKOZBWBEA-UHFFFAOYSA-N n-[2-[(2,3-dihydro-1h-inden-1-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=C2CCC(CNC3C4=CC=CC=C4CC3)OC2=CC=1NS(=O)(=O)C1=CC=CC=C1 ORLIARKOZBWBEA-UHFFFAOYSA-N 0.000 claims 1
- XREPGWKDFACLAF-UHFFFAOYSA-N n-[2-[(2,6-dimethylpiperidin-1-yl)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound CC1CCCC(C)N1CC1OC2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2CC1 XREPGWKDFACLAF-UHFFFAOYSA-N 0.000 claims 1
- VFBAHPKGBZTJNB-UHFFFAOYSA-N n-[2-[(3-butoxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNCCCOCCCC)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 VFBAHPKGBZTJNB-UHFFFAOYSA-N 0.000 claims 1
- GVHRPFFOWXVQLX-UHFFFAOYSA-N n-[2-[(3-hydroxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(CCC(CNCCCO)O2)C2=C1 GVHRPFFOWXVQLX-UHFFFAOYSA-N 0.000 claims 1
- JBOQIPSUVREQCA-UHFFFAOYSA-N n-[2-[(3-hydroxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNCCCO)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 JBOQIPSUVREQCA-UHFFFAOYSA-N 0.000 claims 1
- LYKLVYXZKFKQCL-UHFFFAOYSA-N n-[2-[(3-hydroxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4CCC(OC4=C3)CNCCCO)=CC=C21 LYKLVYXZKFKQCL-UHFFFAOYSA-N 0.000 claims 1
- NMNLZKVFAIEKKD-UHFFFAOYSA-N n-[2-[(3-phenoxypropylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCCCOC1=CC=CC=C1 NMNLZKVFAIEKKD-UHFFFAOYSA-N 0.000 claims 1
- FQUZKJPVIJUETI-UHFFFAOYSA-N n-[2-[(4-phenylbutan-2-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1CC2=CC=C(NS(=O)(=O)C=3C=CC=CC=3)C=C2OC1CNC(C)CCC1=CC=CC=C1 FQUZKJPVIJUETI-UHFFFAOYSA-N 0.000 claims 1
- HXOIGDPVNAKTPZ-UHFFFAOYSA-N n-[2-[(6-methylheptan-2-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNC(C)CCCC(C)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 HXOIGDPVNAKTPZ-UHFFFAOYSA-N 0.000 claims 1
- CRIAMUZXQQEDGS-UHFFFAOYSA-N n-[2-[(benzylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCC1=CC=CC=C1 CRIAMUZXQQEDGS-UHFFFAOYSA-N 0.000 claims 1
- GUOCWZSITCMHCG-UHFFFAOYSA-N n-[2-[(propan-2-ylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNC(C)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 GUOCWZSITCMHCG-UHFFFAOYSA-N 0.000 claims 1
- IJURTMPWEYPMSZ-UHFFFAOYSA-N n-[2-[(pyridin-3-ylmethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCC1=CC=CN=C1 IJURTMPWEYPMSZ-UHFFFAOYSA-N 0.000 claims 1
- GJXCJBIDAZVKSP-UHFFFAOYSA-N n-[2-[(pyridin-4-ylmethylamino)methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1O2)=CC=C1CCC2CNCC1=CC=NC=C1 GJXCJBIDAZVKSP-UHFFFAOYSA-N 0.000 claims 1
- GBKCFXXCHCAHQA-UHFFFAOYSA-N n-[2-[[(1-hydroxy-2-methylpropan-2-yl)amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CNC(C)(CO)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 GBKCFXXCHCAHQA-UHFFFAOYSA-N 0.000 claims 1
- SZTSARCCKVNOPN-UHFFFAOYSA-N n-[2-[[(3-methoxyphenyl)methylamino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound COC1=CC=CC(CNCC2OC3=CC(NS(=O)(=O)C=4C=CC=CC=4)=CC=C3CC2)=C1 SZTSARCCKVNOPN-UHFFFAOYSA-N 0.000 claims 1
- KSFITRJYLAFIHR-UHFFFAOYSA-N n-[2-[[2-(2-hydroxyethyl)piperidin-1-yl]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound OCCC1CCCCN1CC1OC2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2CC1 KSFITRJYLAFIHR-UHFFFAOYSA-N 0.000 claims 1
- IZDZOJUPEPKONT-ZZWBGTBQSA-N n-[2-[[[(1r)-1-cyclohexylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C1CCCCC1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 IZDZOJUPEPKONT-ZZWBGTBQSA-N 0.000 claims 1
- QLSUJDYZWSBRGE-QRIPLOBPSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-2,1,3-benzoxadiazole-4-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C=4C5=NON=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 QLSUJDYZWSBRGE-QRIPLOBPSA-N 0.000 claims 1
- SMXLSSFADRHULS-PLEWWHCXSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 SMXLSSFADRHULS-PLEWWHCXSA-N 0.000 claims 1
- NDCPPWBMKVPNDX-PLEWWHCXSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 NDCPPWBMKVPNDX-PLEWWHCXSA-N 0.000 claims 1
- ROQBLRJFXQWFLB-ZZWBGTBQSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-ZZWBGTBQSA-N 0.000 claims 1
- MPUPRKCXYAKXGG-VGOKPJQXSA-N n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3CC2)C)=CC=CC=C1 MPUPRKCXYAKXGG-VGOKPJQXSA-N 0.000 claims 1
- OCRAGFDGDHKJRX-YANBTOMASA-N n-[2-[[[(1r)-2-hydroxy-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@@H](CO)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 OCRAGFDGDHKJRX-YANBTOMASA-N 0.000 claims 1
- ROQBLRJFXQWFLB-HXBUSHRASA-N n-[2-[[[(1s)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C1=CC=CC=C1 ROQBLRJFXQWFLB-HXBUSHRASA-N 0.000 claims 1
- IQANGFUDFZONKO-FIWHBWSRSA-N n-[2-[[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]benzenesulfonamide Chemical compound C1=C2OC(CN[C@@H](CO)CC(C)C)CCC2=CC=C1NS(=O)(=O)C1=CC=CC=C1 IQANGFUDFZONKO-FIWHBWSRSA-N 0.000 claims 1
- DIBJLKROTYKRAC-RBFZIWAESA-N n-[4-methyl-5-[[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]sulfamoyl]-1,3-thiazol-2-yl]acetamide Chemical compound N([C@H](C)C=1C=CC=CC=1)CC(OC1=C2)CCC1=CC=C2NS(=O)(=O)C=1SC(NC(C)=O)=NC=1C DIBJLKROTYKRAC-RBFZIWAESA-N 0.000 claims 1
- RGDYZZALLDWINK-OSMGYRLQSA-N n-methyl-n-[2-[[[(1r)-1-phenylethyl]amino]methyl]-3,4-dihydro-2h-chromen-7-yl]naphthalene-1-sulfonamide Chemical compound C1([C@H](NCC2OC3=CC(=CC=C3CC2)N(C)S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C)=CC=CC=C1 RGDYZZALLDWINK-OSMGYRLQSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000962 organic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32695701P | 2001-10-04 | 2001-10-04 | |
| PCT/US2002/030955 WO2003029238A1 (en) | 2001-10-04 | 2002-09-30 | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505586A JP2005505586A (ja) | 2005-02-24 |
| JP2005505586A5 true JP2005505586A5 (enExample) | 2005-12-22 |
Family
ID=23274503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532487A Pending JP2005505586A (ja) | 2001-10-04 | 2002-09-30 | ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6706757B2 (enExample) |
| EP (1) | EP1432696A1 (enExample) |
| JP (1) | JP2005505586A (enExample) |
| CN (1) | CN1561338A (enExample) |
| BR (1) | BR0213094A (enExample) |
| CA (1) | CA2461381A1 (enExample) |
| MX (1) | MXPA04003087A (enExample) |
| WO (1) | WO2003029238A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| MXPA06012621A (es) * | 2004-05-05 | 2006-12-15 | Hoffmann La Roche | Arilsulfonil benzodioxanos utiles para la modulacion del receptor 5-ht6, el receptor 5-ht2a o ambos. |
| ATE477248T1 (de) * | 2004-09-30 | 2010-08-15 | Hoffmann La Roche | Benzoxazin- und chinoxalinderivate und anwendungen |
| ES2348467T3 (es) * | 2004-09-30 | 2010-12-07 | F. Hoffmann-La Roche Ag | Derivados y usos de la benzoxazina y la quinoxalina. |
| EP1812416B1 (en) * | 2004-10-14 | 2013-08-21 | Abbott GmbH & Co. KG | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| BRPI0515835A (pt) * | 2004-12-21 | 2008-08-12 | Hoffmann La Roche | derivados de tetralina e de indano e seus usos |
| PT1831159E (pt) * | 2004-12-21 | 2010-03-03 | Hoffmann La Roche | Derivados de tetralina e de indano e as suas utilizações |
| CA2591800A1 (en) * | 2004-12-21 | 2006-06-29 | F.Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof as 5-ht antagonists |
| ES2306275T3 (es) * | 2004-12-21 | 2008-11-01 | F. Hoffmann-La Roche Ag | Derivados de cromano y sus usos como ligandos dde receptores 5-ht. |
| JP4738418B2 (ja) | 2004-12-21 | 2011-08-03 | エフ．ホフマン−ラ ロシュ アーゲー | クロマン誘導体及びｃｎｓ障害の処置におけるその使用 |
| CN101120002A (zh) | 2005-02-17 | 2008-02-06 | 惠氏公司 | 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物 |
| CA2604915A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combinations for the treatment or prevention of depression |
| JP2008538576A (ja) | 2005-04-22 | 2008-10-30 | ワイス | クロマンおよびクロメン誘導体およびその使用 |
| AU2006239897A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| AR054044A1 (es) * | 2005-05-23 | 2007-05-30 | Astrazeneca Ab | Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad. |
| AR054363A1 (es) * | 2005-05-23 | 2007-06-20 | Astrazeneca Ab | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 |
| WO2007051735A1 (en) * | 2005-11-03 | 2007-05-10 | F. Hoffmann-La Roche Ag | Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
| JP2009541248A (ja) * | 2006-06-20 | 2009-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | アリールスルホンアミジルテトラリン誘導体及びそれらの使用 |
| KR101066306B1 (ko) * | 2006-06-20 | 2011-09-20 | 에프. 호프만-라 로슈 아게 | 테트랄린 및 인데인 유도체 및 이들의 용도 |
| WO2007147763A1 (en) * | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Arylsulfonyl naphthalene derivatives and uses thereof |
| CL2007003044A1 (es) * | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
| AR063372A1 (es) * | 2006-10-25 | 2009-01-21 | Wyeth Corp | Derivados de cromano, su sintesis e intermediarios |
| WO2009133107A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| DK2271638T3 (da) | 2008-04-29 | 2011-11-28 | Nsab Af Neurosearch Sweden Ab | Modulatorer af dopaminneurotransmission |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4135474A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| CA2142471A1 (en) * | 1992-08-17 | 1994-03-03 | Hiroshi Koga | Benzopyran and benzoxazine derivatives |
| US6448269B1 (en) * | 1993-07-22 | 2002-09-10 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
| DE69433401T2 (de) * | 1993-08-19 | 2004-09-16 | Janssen Pharmaceutica N.V. | Gefässverengende dihydrobenzopyranderivate |
| US5663194A (en) * | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| US6191164B1 (en) * | 1996-05-15 | 2001-02-20 | Hoechst Aktiengesellschaft | Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them |
| RU2190609C2 (ru) * | 1996-12-10 | 2002-10-10 | Бристол-Маерс Сквибб Компани | Производные бензодиоксола, бензофурана, дигидробензофурана и бензодиоксана и содержащие их композиции |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| EP1054881B1 (en) * | 1997-12-19 | 2008-07-30 | Bayer Corporation | Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| US6051586A (en) * | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| GB9813949D0 (en) * | 1998-06-29 | 1998-08-26 | Smithkline Beecham Plc | Novel compounds |
| RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
| FR2787789B1 (fr) * | 1998-12-29 | 2002-06-14 | Lipha | Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations |
| SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| ATE309995T1 (de) * | 1999-08-26 | 2005-12-15 | Aventis Pharma Inc | Substituierte (aminoiminomethyl oder aminomethyl) dihydrobenzofurane und benozopyrane |
| ATE311378T1 (de) * | 1999-09-17 | 2005-12-15 | Nissan Chemical Ind Ltd | Benzopyran derivate |
| US6323238B1 (en) * | 1999-10-21 | 2001-11-27 | Dongbu Hannong Chemical Co., Ltd. | Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
-
2002
- 2002-09-30 CA CA002461381A patent/CA2461381A1/en not_active Abandoned
- 2002-09-30 JP JP2003532487A patent/JP2005505586A/ja active Pending
- 2002-09-30 CN CNA028193342A patent/CN1561338A/zh active Pending
- 2002-09-30 WO PCT/US2002/030955 patent/WO2003029238A1/en not_active Ceased
- 2002-09-30 EP EP02800383A patent/EP1432696A1/en not_active Withdrawn
- 2002-09-30 BR BR0213094-7A patent/BR0213094A/pt not_active IP Right Cessation
- 2002-09-30 MX MXPA04003087A patent/MXPA04003087A/es unknown
- 2002-10-02 US US10/263,890 patent/US6706757B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6515002B2 (en) | Compounds and compositions for treating C1s-mediated diseases and conditions | |
| CA2418652C (en) | Novel 3-substituted urea derivatives and medicinal use thereof | |
| JP4751567B2 (ja) | 新規アミド誘導体およびその医薬としての用途 | |
| JP2005526723A5 (enExample) | ||
| US7265246B2 (en) | Indane derivates as muscarinic receptor agonists | |
| US6562840B1 (en) | Heteroaryl amidines, methylamidines and guanidines, and the use thereof as protease inhibitors | |
| JP2004525951A5 (enExample) | ||
| CA2384974A1 (en) | Compounds and pharmaceutical compositions as cathepsin s inhibitors | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| JP2005533004A5 (enExample) | ||
| RU2004105260A (ru) | Производные 8-метокси(1,2,4)триазоло(1,5-а)пиридина и их применение в качестве лигандов рецептора аденозина | |
| CN106458940A (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| JP2009537542A5 (enExample) | ||
| JP2005505586A (ja) | ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体 | |
| JP2010526867A5 (enExample) | ||
| JP2008545686A5 (enExample) | ||
| RU2006123418A (ru) | Новые антагонисты м3 мускаринового ацетилхолинового рецептора | |
| JP2008542365A5 (enExample) | ||
| CA2362390A1 (en) | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors | |
| AU2012352572B2 (en) | Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators | |
| JP2023546224A5 (enExample) | ||
| CN1170402A (zh) | 用作抗心率失常药的硝基苯甲酰胺 | |
| JP2024532729A5 (enExample) | ||
| TH91932A (th) | สารประกอบใหม่ | |
| RU2025102588A (ru) | Фармацевтические композиции, содержащие ингибиторы геликазы wrn |